NasdaqCM:FMNB
NasdaqCM:FMNBBanks

A Look At Farmers National Banc (FMNB) Valuation After Recent Share Price Weakness

Farmers National Banc (FMNB) is back on investors’ radar after recent share price moves, with the stock closing at $12.85 and showing mixed returns over the past week, month, and past 3 months. See our latest analysis for Farmers National Banc. At a share price of $12.85, Farmers National Banc has seen short term weakness, with a 7 day share price return of a 7.62% decline, while longer term total shareholder returns over three and five years sit at 2.99% and 14.51% respectively. This may...
NasdaqGS:IONS
NasdaqGS:IONSBiotechs

Has Ionis Pharmaceuticals (IONS) Run Too Far After Its 152% One Year Surge?

If you are wondering whether Ionis Pharmaceuticals at US$83.88 is starting to look expensive or still offers value, you are not alone. The stock has returned 2.6% over the last 7 days, 6.2% over 30 days, 5.3% year to date and 151.7% over the past year, with 103.6% over 3 years and 41.2% over 5 years, which will naturally shape how investors think about its risk and return profile. Recent coverage around Ionis has focused on its position in the pharmaceuticals and biotech space, where...
NasdaqGS:LYFT
NasdaqGS:LYFTTransportation

How Lyft’s (LYFT) Board Adding a Safety and AV Veteran Has Changed Its Investment Story

Lyft has appointed transportation safety veteran Deborah Hersman to its Board of Directors and Nominating and Corporate Governance Committee, effective January 25, 2026, drawing on her experience at the National Transportation Safety Board, National Safety Council, and Waymo. Her combination of safety, regulatory, and autonomous vehicle expertise gives Lyft a governance voice deeply rooted in both public policy and emerging mobility technology. We’ll now examine how Hersman’s safety and...
NYSE:LC
NYSE:LCConsumer Finance

LendingClub (LC) Earnings Surge 164% As Margin Story Tests Bullish Narratives

LendingClub (LC) has wrapped up FY 2025 with fourth quarter revenue of US$354.0 million and basic EPS of US$0.36, set against a trailing twelve month EPS of US$1.18 on revenue of about US$1.33 billion. Over the past year, the company has seen revenue move from US$1.16 billion to roughly US$1.33 billion on a trailing basis, while EPS shifted from US$0.46 to US$1.18, alongside earnings growth of 164.3%. Together with higher reported profit margins compared with the prior year, these results...
NYSE:PWR
NYSE:PWRConstruction

A Look At Quanta Services (PWR) Valuation After Fresh Bullish Analyst Calls For 2026

Recent analyst commentary on Quanta Services (PWR) has turned more upbeat, with Wolfe Research and Seaport Research highlighting the company’s exposure to power, gas, transmission, data center projects, and clean energy demand. See our latest analysis for Quanta Services. The recent upbeat research coverage has landed on a stock that already has strong momentum, with a 30 day share price return of 12.74% and a 1 year total shareholder return of 56.48%, while the 5 year total shareholder...
NasdaqGS:AMAT
NasdaqGS:AMATSemiconductor

Applied Materials Faces Rich Valuation As AI Fab Spending Accelerates

Semiconductor capital spending is surging as chipmakers commit more funds to wafer fab equipment for AI and advanced process nodes. Applied Materials (NasdaqGS:AMAT) is positioned as a key supplier of tools used in Gate-All-Around transistors and Backside Power Delivery technologies. Industry commentary points to a structural shift in global chip manufacturing investment that goes beyond routine quarterly spending cycles. Applied Materials, listed on NasdaqGS:AMAT, supplies equipment and...
NasdaqGM:SMMT
NasdaqGM:SMMTBiotechs

Reassessing Summit Therapeutics (SMMT) After Sharp Pullback And DCF Upside Potential

If you are wondering whether Summit Therapeutics' share price still reflects its true worth after a volatile few years, you are not alone. The stock trades at US$15.40, with returns of an 11.3% decline over the past week, 11.9% decline over the past month, 12.1% decline year to date and 31.1% decline over the last year, set against a very large gain of around 3x over three years and 99.5% gain over five years. Recent news around Summit Therapeutics has focused on its position within the...
NYSE:DEA
NYSE:DEAOffice REITs

A Look At Easterly Government Properties (DEA) Valuation After Strong Quarterly Results And Recent Share Price Gains

Quarterly results move Easterly Government Properties (DEA) into focus On October 27, Easterly Government Properties (DEA) reported quarterly results that management described as supporting consistent, compounding growth. This message coincided with an 11% stock gain over the past month. See our latest analysis for Easterly Government Properties. That upbeat earnings message has arrived after a mixed run, with an 8.3% 30 day share price return and 6.9% 90 day share price return, but a 1 year...
NYSE:NKE
NYSE:NKELuxury

Does Nike’s U.S. Job Cuts And Automation Push Reshape The Bull Case For NIKE (NKE)?

Nike recently announced it will cut about 775 jobs at its U.S. distribution centers in Tennessee and Mississippi as it consolidates facilities and increases automation to simplify its supply chain. Beyond cost-cutting, the move highlights how Nike is reshaping its operational backbone, leaning more heavily on technology to support its long-term turnaround efforts. We’ll now examine how this push toward greater automation and supply-chain simplification shapes Nike’s broader investment...
NYSE:HCA
NYSE:HCAHealthcare

A Look At HCA Healthcare (HCA) Valuation After Strong Results Outlook And New US$10b Buyback Program

HCA Healthcare (HCA) drew fresh attention after releasing fourth quarter and full year 2025 results, reporting higher sales and net income alongside a 2026 profit outlook above analyst expectations, a new US$10b share buyback program, and an increased dividend. See our latest analysis for HCA Healthcare. The shares have been volatile around the earnings release, with a 1 day share price return of -1.77% taking the price to US$482.53, but a 7 day share price return of 3.47% and 90 day share...
NasdaqGS:HNST
NasdaqGS:HNSTPersonal Products

Assessing Honest Company (HNST) Valuation After Mixed Earnings And Business Exit Plans

Honest Company (HNST) is back in focus after reporting mixed earnings, with profits ahead of expectations but sales lagging, and announcing plans to exit the Canadian market and its baby apparel business. See our latest analysis for Honest Company. The latest announcements appear to be weighing on sentiment, with Honest Company’s 90 day share price return of a 28.45% decline and 1 year total shareholder return of a 63.58% loss pointing to fading momentum even as management refocuses the...
NYSE:VVX
NYSE:VVXAerospace & Defense

The Bull Case For V2X (VVX) Could Change Following New Amazon AI Logistics Partnership – Learn Why

V2X, Inc. recently announced a partnership with Amazon to deploy smart warehousing and automation technologies, including advanced computer-vision AI, across V2X-managed warehouses serving U.S. Government customers. This collaboration highlights how combining Amazon’s robotics and AI capabilities with V2X’s mission support footprint could reshape logistics, readiness, and decision-making for complex government operations. We’ll now examine how this Amazon-enabled push into AI-driven smart...
NasdaqGS:FORM
NasdaqGS:FORMSemiconductor

FormFactor Faces Profitability Test As Investments Strain Cash And Earnings

FormFactor (NasdaqGS:FORM) is facing long term profitability questions as revenue growth has lagged semiconductor peers over the past five years. Earnings per share have weakened over the same period, raising concerns about the company’s ability to translate sales into sustainable profit. Free cash flow margins have deteriorated as FormFactor has committed to heavier investment outlays, increasing financial strain. FormFactor, a provider of semiconductor testing and measurement solutions,...
NYSE:CBAN
NYSE:CBANBanks

Colony Bankcorp (CBAN) Net Interest Margin Recovery Tests Bullish Profitability Narratives

Colony Bankcorp (CBAN) has just wrapped up FY 2025 with Q4 total revenue of US$35.3 million and basic EPS of US$0.42, while trailing 12 month revenue came in at US$127.7 million and EPS at US$1.59. The company has seen revenue move from US$112.4 million to US$127.7 million on a trailing 12 month basis, with EPS over the same window going from US$1.36 to US$1.59. With a trailing net profit margin of 22.1% and analysts pointing to further earnings and revenue growth, the latest results give...
NYSE:FFWM
NYSE:FFWMBanks

First Foundation (FFWM) Q4 Loss Persists And Keeps Bearish Profitability Narratives In Focus

First Foundation (FFWM) just posted its FY 2025 fourth quarter numbers with total revenue of US$54.9 million and a basic EPS loss of US$0.10, as the bank continues to work through a period of unprofitable results. Over the past year, the company has seen trailing twelve month revenue of US$170.5 million against a basic EPS loss of US$1.88, which sets a clear backdrop of earnings pressure even as top line activity remains meaningful. With margins still under strain, the latest release puts the...
NYSE:MSI
NYSE:MSICommunications

Is Motorola Solutions (MSI) Fairly Priced After Recent Public Safety Focus And DCF Signal

If you are wondering whether Motorola Solutions at around US$403 per share looks expensive or reasonable, it helps to step back and look at what the current price actually reflects about the business. The stock has returned 1.4% over the last 7 days and 5.0% over the last 30 days, while the year to date return sits at 5.8% and the 1 year return is a 13.8% decline, compared with a 62.9% return over 3 years and 135.1% over 5 years. Recent news coverage around Motorola Solutions has focused on...
NasdaqGS:DXCM
NasdaqGS:DXCMMedical Equipment

Assessing DexCom (DXCM) Valuation After Barclays Downgrade On Rising CGM Competition

DexCom (DXCM) is back in focus after Barclays downgraded the stock to Underweight, citing intensifying competition in its core insulin-intensive markets projected for 2026 and 2027, and raising questions about valuation. See our latest analysis for DexCom. At a share price of US$74.0, DexCom has seen a 27.10% 90 day share price return and a 10.35% 30 day share price return. However, its 1 year total shareholder return shows a 15.54% decline, signaling fading longer term momentum even as short...
NYSE:ARCO
NYSE:ARCOHospitality

How Arcos Dorados’ 2026 Restaurant Expansion Plan At Arcos Dorados Holdings (ARCO) Has Changed Its Investment Story

Arcos Dorados Holdings Inc., the master franchisee for McDonald’s in Latin America and the Caribbean, has announced plans to open between 105 and 115 new restaurants across its operating footprint in 2026. This expansion plan highlights the company’s continued emphasis on unit growth, even as its margins and free cash flow levels have constrained its ability to fund major initiatives internally. We’ll now examine how this planned restaurant rollout for 2026 could influence Arcos Dorados’...
NYSE:WRB
NYSE:WRBInsurance

Record Earnings, Buybacks and AI Push Could Be A Game Changer For W. R. Berkley (WRB)

In late January 2026, W. R. Berkley reported fourth-quarter 2025 results showing revenue of US$3,721.41 million and net income of US$449.51 million, alongside the completion of a long-running US$4.33 billion share repurchase program that has retired over 161 million shares since 2006. Despite the slight quarterly revenue shortfall versus expectations, the insurer delivered record operating earnings and strong underwriting income growth while committing substantial capital to technology and...
NasdaqGS:XRX
NasdaqGS:XRXTech

Xerox Holdings (XRX) Earnings Losses Reinforce Long Running Profit Decline Concerns

Xerox Holdings (XRX) closed out FY 2025 with Q4 revenue of US$2.0 billion and a basic EPS loss of US$0.60, alongside trailing twelve month EPS of US$8.25 in losses on US$7.0 billion of revenue. Over recent quarters, the company has seen revenue move from US$1.5 billion in Q3 2024 to US$2.0 billion in Q4 2025, while quarterly EPS swung between a loss of US$9.72 in Q3 2024 and a loss of US$0.60 in the latest period. This sets up a story in which margin pressure and loss-making results sit at...
NYSE:CRBG
NYSE:CRBGDiversified Financial

Is Corebridge (CRBG) Using Crypto‑Linked Annuities To Redefine Its Retirement Income Strategy?

Corebridge Financial recently introduced the Invesco New Economy Index within its Power Select Index Annuities, offering exposure to areas such as cryptocurrency through allocations to the Invesco QQQ ETF and Invesco Galaxy Bitcoin ETF. This move positions Corebridge at the intersection of retirement income products and newer asset classes, potentially appealing to investors who want market-linked growth potential with principal protection features. We’ll now examine how this new index...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

Apellis Pharmaceuticals (APLS) Valuation Check As Shares Trade Around US$23 After Mixed Return Performance

With no single headline event driving it today, Apellis Pharmaceuticals (APLS) is drawing attention because its share price sits at US$23.05, alongside mixed recent return figures and growing revenue and net income. See our latest analysis for Apellis Pharmaceuticals. At US$23.05, the recent 7 day share price return of 4.77% comes after a 30 day share price return decline of 8.68%. Meanwhile, the 1 year total shareholder return of 24.15% and 3 year total shareholder return of 59.37% both sit...
NasdaqGS:SBUX
NasdaqGS:SBUXHospitality

Starbucks Shareholder Proposals Put Social Risks And Turnaround Under Spotlight

Starbucks (NasdaqGS:SBUX) shareholders have filed multiple proposals ahead of the March annual general meeting. The resolutions target employee benefits, gender-related compensation gaps, board structure, religious charities in gift matching, and corporate diagnostic tools. These items put social responsibility, human capital management, and governance practices under closer scrutiny. For investors watching Starbucks at a share price of $93.88, this cluster of proposals spotlights non...
NasdaqGS:META
NasdaqGS:METAInteractive Media and Services

Meta Platforms (META) Margin Compression Challenges Bullish Growth Narratives In FY 2025 Results

Meta Platforms FY 2025 earnings snapshot Meta Platforms (META) has wrapped up FY 2025 with fourth quarter revenue of about US$59.9b and basic EPS of US$9.02, alongside net income of roughly US$22.8b. The latest twelve month figures show total revenue of about US$201.0b with basic EPS of US$23.98 and net income of around US$60.5b. The company has seen quarterly revenue move from roughly US$48.4b and EPS of US$8.24 in Q4 2024 to about US$59.9b and EPS of US$9.02 in Q4 2025, with trailing net...